EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.

about

Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.

P2860

Q34345596-48C09CB7-39CD-4C7C-A4E3-2DA35E732CE6

P2860

EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.

Item

http://www.wikidata.org/entity/Q40761878

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

2000年學術文章

@zh

2000年學術文章

@zh-hant

name

EORTC 10941: A phase II study ...... ive' metastatic breast cancer.

@en

type

Item

label

EORTC 10941: A phase II study ...... ive' metastatic breast cancer.

@en

prefLabel

EORTC 10941: A phase II study ...... ive' metastatic breast cancer.

@en

P1476

EORTC 10941: A phase II study ...... ive' metastatic breast cancer.

@en

P2093

Beex L

http://www.w3.org/2001/XMLSchema#string

Boes GH

http://www.w3.org/2001/XMLSchema#string

Coleman R

http://www.w3.org/2001/XMLSchema#string

Hamilton A

http://www.w3.org/2001/XMLSchema#string

Klijn J

http://www.w3.org/2001/XMLSchema#string

Mauriac L

http://www.w3.org/2001/XMLSchema#string

Palmer P

http://www.w3.org/2001/XMLSchema#string

Paridaens R

http://www.w3.org/2001/XMLSchema#string

Piccart M

http://www.w3.org/2001/XMLSchema#string

Roy JA

http://www.w3.org/2001/XMLSchema#string

P2860

Ketoconazole and liarozole in the treatment of advanced prostatic cancer.

The antiproliferative activity of all-trans-retinoic acid catabolites and isomers is differentially modulated by liarozole-fumarate in MCF-7 human breast cancer cells.

Assessing the reliability of two toxicity scales: implications for interpreting toxicity data.

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

P2888

a:1006398518037

P304

181-188

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1023/A:1006398518037

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2000-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1004324451

http://www.w3.org/2001/XMLSchema#string

P698

10845281

http://www.w3.org/2001/XMLSchema#string

EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.

about

P2860

P2860

EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698